Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers
Journal of Cancer Research and Clinical Oncology · 2025
DOI: 10.1007/s00432-025-06231-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Maria Raposo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Medicina, Universidade do Porto, Porto, Portugal. up201909621@up.pt. Hauptthemen laut MEDLINE: Quality of Life, Breast Neoplasms, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade do Porto.
Abstract (Originalsprache)
Purpose
Women with pathogenic/likely pathogenic (P/LP) variants in BRCA1/2 genes have an increased lifetime risk of breast and ovarian cancer. Cancer risk management options include intensive breast surveillance (IBS) and risk reducing mastectomy (RRM). This study aims to compare the effect of these strategies on quality of life, anxiety, and depression to enhance shared decision-making.
Methods
We retrospectively analysed clinical records of 221 women with P/LP variants in BRCA1/2 genes, from 2007 to 2024. A total of 169 questionnaires containing Hospital Anxiety and Depression Scale (HADS ) and BREAST-Q were sent, from May to September 2024. Ninety-nine women, 48 who had undergone RRM and 51 who had opted for IBS, completed the questionnaires. Patient-reported outcome measures (PROMs) were compared based on their choice.
Results
Significant differences were found in age at genetic testing and personal history of breast cancer between the groups. In BREAST-Q , the IBS group reported higher scores, with statistically significant differences for Satisfaction with Breasts and Physical Well-Being: Chest. These differences were only observed in the group of women without personal breast cancer history who underwent RRM.
Conclusions
No significant differences were found in psychologic distress levels between the IBS and RRM group. Although RRM is an effective method for reducing breast cancer risk in women with P/LP variants in BRCA1/2 genes, carriers should be informed of its impact on quality of life. Notably, once a woman is diagnosed with breast cancer, these differences lose effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Medicina, Universidade do Porto, Porto, Portugal. up201909621@up.pt.
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
- Breast Center, Unidade Local de Saúde de São João, Porto, Portugal.
- EPIUnit-Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
- Laboratory for Integrative and Translation Research in Population Health (ITR), Universidade do Porto, Porto, Portugal.
- Unidade de Saúde Familiar São João, Unidade Local de Saúde Entre Douro e Vouga, São João da Madeira, Portugal.
Förderung
- Universidade do Porto
Zitieren
APA
Raposo, M., Peleteiro, B., Magalhães, A., Torres, S., Insua-Pereira, I., Guimarães, R., Garrido, L., Costa, S., & Fougo, J. L. (2025). Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06231-9
Vancouver
Raposo M, Peleteiro B, Magalhães A, Torres S, Insua-Pereira I, Guimarães R, et al. Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06231-9
BibTeX
@article{Raposo2025,
author = {Raposo, Maria and Peleteiro, Bárbara and Magalhães, André and Torres, Sandra and Insua-Pereira, Inês and Guimarães, Raquel and Garrido, Luzia and Costa, Susy and Fougo, José Luis},
title = {Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2025},
doi = {10.1007/s00432-025-06231-9}
}
EUVIMED